Akari Therapeutics Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di Akari Therapeutics diminuiranno a una percentuale pari a 14.3% all'anno. Si prevede che l'EPS crescerà a una percentuale pari a 61.2% all'anno.

Informazioni chiave

-14.3%

Tasso di crescita degli utili

61.18%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	24.7%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	20 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Sep 27

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics press release (NASDAQ:AKTX): Q2 GAAP EPS of $0.00. As of June 30, 2022, the Company had cash of approximately $8.2 million, compared to cash of approximately $9.4 million as of December 31, 2021.

Articolo di analisi • Sep 20

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Jul 28

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics (NASDAQ:AKTX) announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration. GA is a chronic progressive degeneration of the macula, which occurs during late-stage dAMD and can lead to irreversible vision loss. The result showed that the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted, the company said.

Seeking Alpha • Jul 20

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics press release (NASDAQ:AKTX): Q1 GAAP EPS of $0.00. At March 31, 2022, the Company had cash of approximately $16.7 million, compared to cash of approximately $9.4 million at December 31, 2021.

Seeking Alpha • Jul 07

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics (NASDAQ:AKTX) on Thursday said a patient had completed a course of treatment with its inhibitor nomacopan in its phase 3 part A trial in kids with hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). HSCT-TMA is a complication that can happen following a stem cell transplant procedure which can lead to tissue hypoxia, blood clots and progressive organ damage and death. AKTX said one of the three patients with severe HSCT-TMA in the trial completed more than 60 days of treatment with nomacopan and was subsequently discharged from the hospital. Another patient died due to multi-organ failure that was unrelated to the treatment with nomacopan. Dosing has started in the third patient. Nomacopan had previously been granted orphan drug and fast track designations by the U.S. FDA for pediatric HSCT-TMA. U.S.-listed shares of AKTX gained 12.6% to $1.07 in early trading.

Articolo di analisi • Dec 31

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Articolo di analisi • Mar 15

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. By way of example, Akari Therapeutics...

Articolo di analisi • Jan 21

Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?

If you want to know who really controls Akari Therapeutics, Plc ( NASDAQ:AKTX ), then you'll have to look at the makeup...

Articolo di analisi • Dec 17

Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:AKTX - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	N/A	-29	N/A	N/A	2
12/31/2027	N/A	-20	N/A	N/A	2
12/31/2026	N/A	-24	N/A	N/A	2
3/31/2026	N/A	-28	-11	-11	N/A
12/31/2025	N/A	-17	-11	-11	N/A
9/30/2025	N/A	-16	-10	-10	N/A
6/30/2025	N/A	-12	-9	-9	N/A
3/31/2025	N/A	-18	-11	-11	N/A
12/31/2024	N/A	-20	-13	-13	N/A
9/30/2024	N/A	-20	-15	-15	N/A
6/30/2024	N/A	-20	-16	-16	N/A
3/31/2024	N/A	-17	-16	-16	N/A
12/31/2023	N/A	-10	-16	-16	N/A
9/30/2023	N/A	-9	-16	-16	N/A
6/30/2023	N/A	-10	-17	-17	N/A
3/31/2023	N/A	-12	-21	-21	N/A
12/31/2022	N/A	-18	-22	-22	N/A
9/30/2022	N/A	-20	-23	-23	N/A
6/30/2022	N/A	-18	-20	-20	N/A
3/31/2022	N/A	-17	-16	-16	N/A
12/31/2021	N/A	-17	-19	-19	N/A
9/30/2021	N/A	-18	-18	-18	N/A
6/30/2021	N/A	-16	-17	-17	N/A
3/31/2021	N/A	-19	-17	-17	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-18	-16	-16	N/A
6/30/2020	N/A	-21	-20	-20	N/A
3/31/2020	N/A	-18	-21	-21	N/A
12/31/2019	N/A	-17	N/A	-13	N/A
9/30/2019	N/A	-13	N/A	-14	N/A
6/30/2019	N/A	-14	N/A	-14	N/A
3/31/2019	N/A	-18	N/A	-18	N/A
12/31/2018	N/A	-20	N/A	-23	N/A
9/30/2018	N/A	-25	N/A	-27	N/A
6/30/2018	N/A	-32	N/A	-30	N/A
3/31/2018	N/A	-24	N/A	-27	N/A
12/31/2017	N/A	-35	N/A	-32	N/A
9/30/2017	N/A	-32	N/A	-30	N/A
6/30/2017	N/A	-22	N/A	-25	N/A
3/31/2017	N/A	-28	N/A	-26	N/A
12/31/2016	N/A	-18	N/A	-25	N/A
9/30/2016	N/A	-3	N/A	-25	N/A
6/30/2016	N/A	-52	N/A	-15	N/A
3/31/2016	N/A	-47	N/A	-10	N/A
12/31/2015	N/A	-45	N/A	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che AKTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che AKTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che AKTX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di AKTX cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Si prevede che AKTX non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di AKTX è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/21 00:58
Prezzo dell'azione a fine giornata	2026/07/21 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Akari Therapeutics, Plc è coperta da 6 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Madhu Kumar	B. Riley Securities, Inc.
Arlinda Lee	Canaccord Genuity
Sean Lee	H.C. Wainwright & Co.

Akari Therapeutics Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 33% to US$153

Price target decreased by 17% to US$96.75

Price target decreased by 95% to US$7.00

Price target decreased to US$4.00

Recent updates

Akari Therapeutics plc Announces Appointment of Patricia LoRusso, D.O. to Scientific Advisory Board

Akari Therapeutics, plc Approves Board Changes

Akari Therapeutics Completes PIPE Raising $8.3 Million to Advance Lead Pipeline Programs

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2026

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of Aktx-101 with Kras Inhibition in Kras-Mutated Pancreatic Cancer Models

Akari Therapeutics, Plc announced that it expects to receive $5.499999 million in funding

Akari Therapeutics, Plc has withdrawn its Follow-on Equity Offering.

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc has filed a Follow-on Equity Offering.

New major risk - Share price stability

Akari Therapeutics, Plc Secures Australian Patent Approval for Proprietary PH1 RNA Splicing Modulator ADC Payload

Price target increased by 33% to US$153

Akari Therapeutics plc Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-In-Class Trop2 ADC Payload Targeting RNA Splicing

Price target decreased by 17% to US$96.75

New major risk - Financial position

New major risk - Market cap size

Akari Therapeutics plc Appoints Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Akari Therapeutics Plc Appoints Olga Anczukow to Its Scientific Advisory Board

Akari Therapeutics, Plc Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

New major risk - Market cap size

Akari Therapeutics, Plc has filed a Follow-on Equity Offering in the amount of $5 million.

Akari Therapeutics, plc Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, Aktx-101, for Hard-To-Treat K-Ras Mutant Pancreatic Cancer

Akari Therapeutics Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing Rule

Akari Therapeutics, Plc, Annual General Meeting, Dec 15, 2025

Akari Therapeutics, Plc Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Akari Therapeutics, plc Announces Appointment of Sara Hurvitz to Its Board

Akari Therapeutics, Plc has filed a Follow-on Equity Offering in the amount of $2.5 million.

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Akari Therapeutics' Preclinical Data Demonstrates the Potential of Its Novel ADC Spliceosome Modulating Payload, PH1

New minor risk - Share price stability

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Akari Therapeutics Continues Key Research on Its Novel Antibody Drug Conjugate Payload Ph1 to Further Demonstrate Its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

New major risk - Revenue and earnings growth

Price target decreased by 95% to US$7.00

High number of new and inexperienced directors

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2025

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Akari Therapeutics, Plc announced delayed annual 10-K filing

New major risk - Share price stability

Akari Therapeutics, Plc Announces Board Changes

Akari Therapeutics, Plc announced that it expects to receive $7.1 million in funding

High number of new directors

Akari Therapeutics, Plc Announces Board Changes

Akari Therapeutics, Plc Appoints Torsten Hombeck as Chief Financial Officer

Wendy Dicicco No Longer Serve as Interim Chief Financial Officer of Akari Therapeutics, Plc

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments